Sign in
Active, not recruitingPhase 1

rTMS in Older Adults With MCI and AUD

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
35 people, planned
Started
1 Nov 2023
Expected to end
30 Nov 2026
Type of study
Interventional
Treatments tested
  • Active, Open Label iTBS-rTMS
Record updated
17 September 2026

Who can take part

Age
60 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Age 60-85
  • English as a first/primary language
  • Current alcohol use disorder
  • Alcohol consumption of at least 4 heavy drinking days (defined as ≥ 4 drinks for women and ≥ 5 for men) per week during the 30-days prior to enrolling
  • Meets actuarial neuropsychological criteria for MCI: ≥2 impaired scores within one cognitive domain, or ≥1 impaired scores in ≥3 domains, where an impaired score is defined as ≤16th percentile using demographically-corrected norms
  • Not pregnant (will administer pregnancy test to confirm)
  • Functional visual and auditory acuity to complete all assessments

Who cannot take part

  • Prior diagnosis of Dementia or Major Neurocognitive Disorder per NIA-AA or DSM-5 criteria, and TICS ≤ 22 suggestive of dementia
  • Daily/weekly anticholinergic or sedative use. Stimulants may be allowed pending investigator review. Cholinesterase inhibitors, NMDA receptor antagonists, and antidepressants are allowed if on a stable regimen of 4 weeks prior to enrollment
  • Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days
  • Current substance use disorder other than AUD or nicotine use disorder, bipolar disorder, or schizophrenia spectrum or other psychotic disorder
  • History of significant or unstable condition/s that may impact cognition such as significant cardiac, cerebrovascular, or metabolic disease, developmental disorder, or other neurologic disease (e.g. movement disorder, moderate to severe brain injury, seizures)
  • MRI and TMS contraindications (e.g. implants, claustrophobia, conditions/treatments that lower seizure threshold, taking medications that have short half-lives, no identifiable motor threshold)
  • Pregnant (will administer pregnancy test to confirm)

Where in United States

  • Medical Univeristy of South CarolinaCharleston, United States
  • Medical University of South CarolinaCharleston, United States

About the trial

What the trial wants to find out

Alcohol misuse is a risk factor for early onset cognitive impairment, contributing to 10% of early onset dementia, with risk corresponding to consumption. Additionally, continued drinking risks worsening cognitive decline and dementia progression, while worsening cognitive impairment contributes to drinking escalation. Repetitive transcranial magnetic stimulation (rTMS) has been shown to improve cognition in Alzheimer's Disease and Related Dimentias (ADRD) and separately reduce heavy drinking in alcohol use disorder. Our objective is to optimize rTMS for simultaneous mitigation of both drinking and cognitive dysfunction in older adults.

The group in the trial

  • Active, Open Label iTBS-rTMSTreatment being tested

    Individuals will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total). All will undergo clinical assessments and brain MRI at pre-treatment and at 1-week post-treatment, and clinical assessments at 4-weeks post-treatment. Weekly post-treatment online self-report assessments will be collected up to four weeks. Resting-state parcellations of pre- and post-fMRI will be completed for personalized targeting and network parcellations.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Targeting the Shared Substrates of Alcohol Misuse and Cognitive Impairment: Accelerated rTMS for Older Adults With Alcohol Use Disorder
Record updated
17 September 2026